Additional file 1 of Age-stratified associations between radiotherapy and SPMs for FPHNC: a population-based cohort study

Additional file 1. Table S1 Site recode ICD-O-3 2023 revision. Table S2 Site recode ICD-O-3/WHO 2008 definition (for SIRs). Table S3 Site of FPHNC among 2- and 5-year survivors [n (%)]. Table S4 Histology recodes of FPHNC among different age groups of 5-year survivors based on histologic type ICD-O-3 [n (%)]. Table S5 Histology recodes of FPHNC among different age groups of 2-year survivors based on Histologic Type ICD-O-3 [n (%)]. Table S6 Collinearity diagnostics for multivariable Fine-Gray competing risk models. Table S7 Collinearity diagnostics for multivariable modified Poisson regression models. Table S8 Baseline characteristics of the 5-year survivors of FPHNC. Table S9 SIRs for solid SPMs: external comparison with the general population by radiotherapy exposure, and IRRs: internal comparison within the cohort by radiotherapy exposure, in 5-year survivors of FPHNC. Table S10 SIRs for solid SPMs, in young 5-year survivors of FPHNC: external comparison with the general population by radiotherapy exposure. Table S11 SIRs for solid SPMs, in middle-aged 5-year survivors of FPHNC: external comparison with the general population by radiotherapy exposure. Table S12 SIRs for solid SPMs, in elderly 5-year survivors of FPHNC: external comparison with the general population by radiotherapy exposure. Table S13 Age- and sex-stratified SIRs for SPMs, in survivors of FPHNC: external comparison with the general population by radiotherapy exposure. Table S14 Baseline characteristics of the 2-year survivors of FPHNC. Table S15 SIRs for hematologic SPMs: external comparison with the general population by radiotherapy exposure, and IRRs: internal comparison within the cohort by radiotherapy exposure in 2-year survivors of FPHNC. Table S16 Age-stratified SIRs for hematologic SPMs, in 2-year survivors of FPHNC: external comparison with the general population by radiotherapy exposure. Fig. S1 Associations between radiotherapy and cumulative incidence of SPMs. Fig. S2 Associations between chemotherapy and cumulative incidence of solid SPMs among 5-year survivors treated with radiotherapy. Fig. S3 IRRs and 95% CIs for solid and hematologic SPMs associated with radiotherapy in FPHNC. Fig. S4 Age-stratified IRRs and 95% CIs for SPMs associated with radiotherapy in FPHNC. Fig. S5 Associations between chemotherapy and cumulative incidence of hematologic SPMs among 2-year survivors treated with radiotherapy.